TIOTROPIUM BROMIDE ADMINISTERED VIA THE RESPIMAT DEVICE IN CF PATIENTS

通过 RESPIMAT 装置对 CF 患者施用噻托溴铵

• 批准号: 7604920
• 负责人: RICHARD C AHRENS
• 金额: $ 0.05万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604920
• 关键词: Blood; Breathing; Computer Retrieval of Information on Scientific Projects Database; Cystic Fibrosis; Daily; Devices; Dose; Double-Blind Method; Exclusion Criteria; Funding; Grant; Home environment; Hour; Institution; Measurement; Patients; Pharmaceutical Preparations; Randomized; Research; Research Personnel; Resources; Safety; Source; Spirometry; United States National Institutes of Health; Urine; day; placebo controlled study; tiotropium bromide

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokineetics of increasing single and multiple doses (28-day dosing) of tiotropium bromide administered once daily via the Respimate device in people with cystic fibrosis. Subjects meeting inclusion/exclusion criteria will receive a single dose of inhaled study medication in the CRC followed by blood, urine sampleing, vital sign measurement and spirometry over 8 hours. Subjects may opt to end the study there or proceed to the multiple dose part of the study (take medication at home, once a day for 28 days). If subjects opt to do both the single and multiple dose part of the study, they must have 30 days in between the dosing And will receive the same dose.

这个子项目是众多研究子项目之一